Chemoradiotherapy for treatment of esophageal cancer in Japan: Current status and perspectives

Gastrointestinal Cancer Research

Volumn 3, Issue 2, 2009, Pages 66-72

  Shitara, Kohei ^a   Muro, Kei ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; FLUOROURACIL; NEDAPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DYSPHAGIA; ENDOSCOPIC SURGERY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; ESOPHAGUS METASTASIS; ESOPHAGUS RESECTION; ESOPHAGUS STENOSIS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; METASTASIS; MULTIPLE CYCLE TREATMENT; PERICARDIAL EFFUSION; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; RADIATION DOSE; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

EID: 77953378883     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Cancer Statistics in Japan, 2008 (http://www.fpcr.or.jp/publication/pdf/ statistics2008.pdf)
2. Vizcaino AP, Moreno V, Lambert R, et al: Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 99:860-868, 2002
3. Shibata A, Matsuda T, Ajiki W, et al: Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993-2001. Jpn J Clin Oncol 38: 464-468, 2008
4. Ueda Y, Fujii Y, Udagawa H: Thoracic and cardiovascular surgery in Japan during 2006: annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 56:365-388, 2008
5. Isono K, Sato H, Nakayama K: Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 48:411-420, 1991
6. Kato H: Lymph node dissection for thoracic esophageal carcinoma. Two- and three-field lymph node dissection. Ann Chir Gynaecol 84:193-199, 1995
7. Mariette C, Piessen G, Triboulet JP: Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8:545-553, 2007
8. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359:1727-1733, 2002
9. Kelsen DP, Ginsberg R, Pajak TF, et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1979-1984, 1998
10. Bosset JF, Gignoux M, Triboulet JP, et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337:161-167, 1997
11. Sun DR: Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol Biol Phys 16:329-334, 1989
12. Newaishy GA, Read GA, Duncan W, et al: Results of radical radiotherapy of squamous cell carcinoma of the oesophagus. Clin Radiol 33:347-352, 1982
13. Okawa T, Kita M, Tanaka M, et al: Results of radiotherapy for inoperable locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 17:49-54, 1989
14. Herskovic A, Martz K, al-Sarraf M, et al: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593-1598, 1992
15. Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281:1623-1627, 1999
16. Minsky BD, Pajak TF, Ginsberg RJ, et al: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high dose versus standard-dose radiation therapy. J Clin Oncol 20:1167-1174, 2002
17. Gebski V, Burmeister B, Smithers BM, et al: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8: 226-234, 2007
18. Bedenne L, Michel P, Bouché O, et al: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25:1160-1168, 2007
19. Stahl M, Stuschke M, Lehmann N, et al: Chemo radiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310-2317, 2005
20. Hironaka S, Ohtsu A, Boku N, et al: Non randomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any)M(0)squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 57:425-433, 2003
21. Registration committee for Esophageal Cancer: Comprehensive Registry of Esophageal Cancer in Japan (1998, 1999) & Long-term Results of Esophagectomy in Japan (ed 3). Tokyo, Japan, Japanese Society for Esophageal Diseases. 1988-1997 (in Japanese)
22. The Japan Esophageal Society: Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus. (ed 10). Tokyo, Japan, Kanehara Shuppan, 2007 (in Japanese)
23. Kakushima N, Fujishiro M: Endoscopic submucosal dissection for gastrointestinal neoplasms. World J Gastroenterol 14:2962-2967, 2008
24. Oyama T, Miyata Y, Shimaya S. Lymph nodal metastasis of m3, sm1 esophageal cancer [in Japanese]. Stomach Intestine 37:71-74, 2002
25. Ura T, Muro K, Shimada Y, et al: Definitive chemoradiotherapy may be standard treatment options in clinical stage I esophageal cancer. Proc Am Soc Clin Oncol 22:317s, 2004 (abstr 4017)
26. Kato H, Udagawa H, Togo A, et al: A phase II trial of chemo-radiotherapy in patients with stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group study (JCOG 9708). Proc Am Soc Clin Oncol 21:286a, 2003 (abstr 1147)
27. Igaki H, Kato H, Tachimori Y, et al: Clinicopathologic characteristics and survival of patients with clinical Stage I squamous cell carcinomas of the thoracic esophagus treated with three-field lymph node dissection. Eur J Cardiothorac Surg 20:1089-1094, 2001
28. Ando N, Ozawa S, Kitagawa Y, et al: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 232:225-232, 2000
29. Ando N, Iizuka T, Ide H, et al: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study - JCOG 9204. J Clin Oncol 21: 4592-4596, 2003
30. Igaki H, Kato H, Ando N, et al: A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). Proc Am Soc Clin Oncol 26:15s, 2008 (abstr 4510)
31. Muro K, Ohtsu A, Ishikura S, et al: A phase II study of chemoradiotherapy in patients with stage II, III esophageal squamous cell carcinoma (ESCC): (JCOG 9906). Proc Am Soc Clin Oncol 25:18s, 2007 (abstr 15137)
32. Kubota T: The role of S-1 in the treatment of gastric cancer. Br J Cancer 98:1301-1304, 2008
33. Iizuka T, Isono K, Kakegawa T, et al: Parameters linked to ten-year survival in Japan of resected esophageal carcinoma. Japanese Committee for Registration of Esophageal Carcinoma Cases. Chest 96:1005-1011, 1989
34. Akiyama H, Tsurumaru M, Udagawa H, et al: Radical lymphnode dissection for cancer of the thoracic esophagus. Ann Surg 220:364-373, 1994
35. Baba M, Aikou T, Yoshinaka H, et al: Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg 219:310-316, 1994
36. Ohtsu A: Chemoradiotherapy for esophageal cancer: current status and perspectives. Int J Clin Oncol 9:444-450, 2004
37. Ohtsu A, Boku N, Muro K, et al: Definitive chemo radiotherapy for T4 and/ or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17:2915-2921, 1999
38. Ishida K, Ando N, Yamamoto S, et al: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/ Japan Clinical Oncology Group Trial (JCOG 9516). Jpn J Clin Oncol 34:615-619, 2004
39. Nishimura Y, Suzuki M, Nakamatsu I: Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys 53:134-139, 2002
40. Kaneko K, Ito H, Konishi I: Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer 88:18-24, 2003
41. Iizuka T, Kakegawa T, Ide H, et al: Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22:172-176, 1992
42. Hayashi K, Ando N, Watanabe H, et al: Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG 9407) Jpn J Clin Oncol 31:419-423, 2001
43. Muro K, Ando N, Nishimaki T, et al: A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) trial (JCOG 9905). Proc Am Soc Clin Oncol 22: 2003 (abstr 1112)
44. Muro K, Hamaguchi T, Ohtsu A, et al: A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15:955-959, 2004
45. Tahara M, Fuse N, Kato K, et al: Weekly paclitaxel in patients with advanced or recurrent esophageal cancer (EC) previously treated with platinum-based chemotherapy: Results of phase II study. Presented at the 2009 Gastrointestinal Cancer Symposium, San Francisco, CA, January 15-17, 2009 (abstr 48)
46. Takashima A, Shirao K, Hirashima Y: Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy. Dis Esophagus 21:607-611, 2008
47. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997, 2006
48. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007
49. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357: 1705-1715, 2007
50. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
51. Safran H, Suntharalingam M, Dipetrillo T, et al: Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 70:391-395, 2008
52. Sgroi MM, Hanna NH, McCollum AD, et al: Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal (GE) junction carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas-South - western. Proc Am Soc Clin Oncol 27:2008 (abstr 4564)
53. Fillos TJ, Hentschel P, Watkins KT, et al: High complete response (CR) rate and 2-year survival rates with no evidence of disease (NED) in patients (pts) with esophageal carcinoma (EC) undergoing neoadjuvant combination of docetaxel and cisplatin (DC) ± cetuximab (DCE) chemoradiation therapy. Presented at the 2008 Gastrointestinal Cancer Symposium, Orlando, FL, January 25-27, 2008 (abstr 121)